WELLNEX Life, Australian consumer healthcare company, has announced today its decision to pursue a dual listing on the London Stock Exchange (LSE), with the aim of accelerating its international expansion.
Chairman Mario Tascone (pictured), said, "I am delighted to announce that we are officially starting the LSE listing process and am excited by the opportunity it presents Wellnex".
"While we continue to concentrate and increase our presence in the domestic market, this will open up opportunities to grow the business by taking advantage of the numerous opportunities internationally."
Tascone said the decision was made following consultation with UK-based advisors and positive feedback from British investors on a recent UK roadshow.
"The move reflects our ambition to access new investors and trade on an international platform alongside the world's leading health and pharmaceutical entities."
It signals the latest in a series of moves by the company to ramp up its international growth, including the expansion of its supply agreement with Haleon to new markets in the UK and UAE.
"Furthermore, through an international distribution agreement with Homart Pharmaceuticals, we're actively pursuing additional international markets for our other brands and products throughout Asia," Tascone said.
He also revealed that Wellnex is in discussions with distributors throughout Europe to market its brands and products into that region's wider market. JM
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Apr 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Apr 24
